Skip to main content
Andreas Schlitzer
© Volker Lannert / Uni Bonn

News categories: Honors & Funding

Highly Cited Researchers 2022

ImmunoSensation is prominently represented in the “Highly Cited Researchers 2022” ranking

The Bonn Cluster of Excellence ImmunoSensation2 once more is strongly represented in this year’s ranking of highly cited researchers. Prof. Eicke Latz, head of the Institute of Innate Immunity at the University Hospital Bonn, Prof. Andreas Schlitzer, head of the Quantitative Systems Biology group at LIMES Institute of Bonn University as well as Prof. Joachim Schultze, Director Systems Medicine at the DZNE, are among the year’s most influential researchers once more.

The researchers on the list of "Highly Cited Researchers" are among the world's most influential one percent of their scientific field, according to the creators of the ranking. The benchmark is the frequency with which their scientific publications have been cited by other scientists in the last ten years (period from 2011 to 2021). The ranking is published annually by the Web of Science Group and includes around 6,200 scientists in 21 subject categories.

Prof. Eicke Latz is awarded as one of the most influential researchers in the field of immunology for the nineth time in a row. He has been ranked as one of the “highly cited researchers” every single year, since 2014. Prof. Andreas Schlitzer receives the award for the fourth time. He has been ranked as “highly cited researcher” in cross-Field annually, starting 2019. Prof. Joachim Schultze is ranked for the second time. He had been among the “highly cited researchers” in cross-Field in 2021 and this year belongs to the most influential researchers in the field of immunology.

The full list of researchers is published by web of science and can be found at https://clarivate.com/highly-cited-researchers/

Related news

Speakers of ImmunoSensation

News categories: Honors & Funding

ImmunoSensation goes into the next round

The Bonn Cluster of Excellence ImmunoSensation will be funded for further seven years as part of the Excellence Strategy of the German federal and state governments. The aim of the new funding period, which begins on January 1, 2026, is to research immune diversity: the structural, functional and dynamic diversity of the immune system. Involved are the University of Bonn, the University Hospital Bonn (UKB) and the German Center for Neurodegenerative Diseases (DZNE). The funding amounts to around 50 million euros.
View entry
Kerstin Ludwig

News categories: Honors & Funding

Genome data to improve diagnosis and treatment of long Covid

Despite the many advances, there are still major gaps in the care of patients with long-term and post-COVID. The Institute of Human Genetics at the UKB in Bonn now begins a genomLC study as part of a BMG funding priority. The researchers want to help speed up the diagnosis of long- and post-COVID and identify possible biomarkers that could possibly also differentiate between subgroups of the diseases. To this end, the genomic data of those affected is being analyzed as part of a study using blood samples. The project is funded by the Federal Ministry of Health (BMG) with 1.34 million euros.
View entry
Reckzeh News

News categories: Honors & Funding

Creating Personalized Cancer Treatments

Bonn researchers aim to improve colon cancer treatment using 3D organoids and digital twins. Funded by the Federal Ministry of Education and Research (BMBF), a collaborative project involving the University of Bonn, the company ESQlabs and the University Hospital Bonn is seeking to refine the therapy recommendations given to colon cancer patients. To this end, “ISPOT-K” is merging organoids taken from patients with the power of digital twin technology.
View entry

Back to the news overview